SMARCA4/BRG1 is a novel prognostic biomarker predictive of outcomes in patients with resected non-small cell lung cancer (NSCLC) receiving cisplatin-based chemotherapy, a study published in the journal Clinical Cancer Research has shown.1

Because it is necessary to identify predictive biomarkers to improve selection of patients who would obtain the most benefit from platinum-based chemotherapy, researchers sought to determine whether decreased expression of SMARCA4/BRG1 predicts increased sensitivity to adjuvant platinum-based therapies in NSCLC. SMARCA4/BRG1 is a known regulator of transcription and DNA repair.

For the study, researchers tested the prognostic value of the gene using a gene-expression microarray of 440 samples from the National Cancer Institute Director’s Challenge Lung Cancer Study.

They assessed the predictive significance using the same method of 133 samples from treatment and control arms of the JBR 10 trial that evaluated adjuvant cisplatin and vinorelbine.

RELATED: FDA-approved ALK CDx More Accurate Than Another IHC Assay

Results showed that reduced expression of SMARCA4 was associated with poor overall survival compared with high and intermediate expression in the Director’s Challenge Study (P < .001 and P = .009, respectively.

A multivariate analysis demonstrated a reduction in the risk of death with high SMARCA4 expression vs low expression (HR, 0.6; 95% CI, 0.4 -0.8; P = .002).

Researchers found that low SMARCA4 expression in patients treated with adjuvant cisplatin and vinorelbine was associated with improved 5-year disease-specific survival (HR, 0.1; 95% CI, 0.0 – 0.5; P = .002).

Reference

  1. Bell EH, Chakraborty AR, Mo X, et al. SMARCA4/BRG1 is a novel prognostic biomarker predictive of cisplatin-based chemotherapy outcomes in resected non–small cell lung cancer [published online ahead of print December 15, 2015]. Clin Cancer Res. doi: 10.1158/1078-0432.CCR-15-1468.